



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/715,962	11/17/2000	Klaus Raming	Mo-5998/LeA-34.074	7971

157 7590 03/05/2002

BAYER CORPORATION  
PATENT DEPARTMENT  
100 BAYER ROAD  
PITTSBURGH, PA 15205

EXAMINER

BRANNOCK, MICHAEL T

ART UNIT	PAPER NUMBER
----------	--------------

1646

DATE MAILED: 03/05/2002

5

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/715,962

Applicant(s)

Raming et al.

Examiner

Michael Brannock, Ph.D.

Art Unit

1646



— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on Aug 27, 2001
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 35 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-8, 10-17, and 26-38 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claims 1-8, 10-17, and 26-38 are subject to restriction and/or election requirements.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some\* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892)
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_\_
- 18) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 19) ☐ Notice of Informal Patent Application (PTO-152)
- 20) ☐ Other: \_\_\_\_\_

Art Unit: 1646

## **DETAILED ACTION**

### ***Election/Restriction***

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1, 2, drawn to polypeptides, classified in class 530, subclass 350.
  - II. Claims 3-8, 10-13, 26-32, drawn to polynucleotides, vectors, host cells and methods of producing a polypeptide, classified in class 536, subclass 23.5.
  - III. Claim 14, drawn to antibodies, classified in class 530, subclass 388.12.
  - IV. Claims 15-17, 33, drawn to transgenic animals, classified in class 800, subclass 3.
  - V. Claims 34 and 37, as claim 37 relates to methods of identifying agonists and antagonists, drawn to methods of identifying agonists and antagonists of a GABAB receptor, classified in class 435, subclass 7.21.
  - VI. Claims 35, drawn to methods of identifying binding partners of a GABAB receptor, classified in class 436, subclass 501.
  - VII. Claims 36 and 37, as claim 37 relates to methods of identifying regulators of gene expression, drawn to methods of identifying regulators of gene expression, classified in class 435, subclass 69.1.
  - VIII. Claim 38, drawn to methods of killing insect pests, classification dependent on the chemical identity of the pesticide.
2. The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1646

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different products, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Groups I-IV are directed to products that are distinct both physically and functionally, and are therefore patentably distinct. Further, the protein of Group I can be prepared by processes which are materially different from recombinant DNA expression of Group II, such as by chemical synthesis, or by isolation and purification from natural sources. Additionally, the DNA of Group II can be used other than to make the protein of Group I, such as in gene therapy or as a probe in nucleic acid hybridization assays. The protein of Group I can be used in materially different methods other than to make the antibody of Group III, such as in therapeutic or diagnostic methods (e.g., in screening). Additionally, although the antibody of Group III can be used to obtain the DNA of Group II, it can also be used in materially different methods, such as in various diagnostic (e.g., in as a probe in immunoassays or immunochromatography), or therapeutic methods. Although the DNA of Group I can be used to make the transgenic animal of Group IV, the DNA can be used in other materially and functionally distinct methods, such as in gene therapy or as a probe in nucleic acid hybridization assays. Finally, the protein of Group I and the antibody of Group II are not required to make the transgenic animal of Group IV.

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different methods, restriction is

Art Unit: 1646

deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Groups V-VIII are directed to methods that are distinct both physically and functionally, and are not required one for the other. Group V requires a functional assay of a GABAB receptor, which is not required by any of the other groups. Group VI requires a ligand binding assay of a GABAB receptor, which is not required by any of the other groups. Group VII requires an assay of gene expression, which is not required by any of the other groups. Group VIII requires an insecticidal assay, which is not required of any of the other groups.

The polypeptides of Group I are related to the methods of Groups V, VI, and VIII as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptides of Group I are patentably distinct from each of the methods of Groups V, VI, and VIII because the polypeptides of Group I can be used in ways that are materially and functionally different than each of the methods because, as discussed above, each of the methods of Groups V, VI, and VIII are materially and functionally distinct from the others. Furthermore, the polypeptides of Group I and the method of Group VII are patentably distinct because one is not required for the use of the other.

The polynucleotides of Group II are related to the methods of Groups V-VII as product and process of use. In the instant case the polynucleotides of Group II are patentably distinct

Art Unit: 1646

from each of the methods of Groups V-VII because the polynucleotides of Group II can be used in ways that are materially and functionally different than each of the methods because, as discussed above, each of the methods of Groups V-VII are materially and functionally distinct from the others. Furthermore, the polynucleotides of Group II and the methods of Group VIII are patentably distinct because one is not required for the use of the other.

The antibodies of Group III are related to the methods of Groups V-VIII as product and process of use. In the instant case the antibodies of Group III are patentably distinct from each of the methods of Groups V-VIII because the antibodies of Group III can be used in ways that are materially and functionally different than each of the methods because, as discussed above, each of the methods of Groups V-VIII are materially and functionally distinct from the others.

The transgenic animals of Group IV are related to the methods of Groups V, VII and VIII as product and process of use. In the instant case the transgenic animals of Group IV are patentably distinct from each of the methods of Groups V, VII and VIII because the transgenic animals of Group IV can be used in ways that are materially and functionally different than each of the methods because, as discussed above, each of the methods of Groups V, VII and VIII are materially and functionally distinct from the others. Furthermore, the transgenic animals of Group IV and the methods of Group VI are patentably distinct because one is not required for the use of the other.

Therefore, because these inventions are distinct for the reasons given above and because a search and examination of all the groups in one patent application would result in an undue

Art Unit: 1646

burden, since the searches for the groups are not co-extensive, the classification is different, and the subject matter is divergent, restriction for examination purposes as indicated is proper.

3. Claims 1-8, 10-17, and 26-38 are generic to a plurality of disclosed patentably distinct species comprising a polypeptide of either SEQ ID NO: 2, 4, or 6, or a polynucleotide of either SEQ ID NO: 1, 3, or 5. Each SEQ ID NO represents a structurally and functionally distinct molecule, the use of one not being required for the use of any other. Further, although a search of one SEQ ID NO may overlap that of another, no two searches would be coextensive, and nor could one search be relied upon to provide art that is anticipatory or might render obvious any other SEQ ID NO; and to search all species in a single application would be unduly burdensome. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, such species being appropriate to the Group chosen, e.g. if Group I is chosen then an appropriate species would be SEQ ID NO: 2, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Art Unit: 1646

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Brannock, Ph.D., whose telephone number is (703) 306-5876. The examiner can normally be reached on Mondays through Thursdays from 8:00 a.m. to 5:30 p.m. The examiner can also normally be reached on alternate Fridays.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

MB

March 3, 2002

  
YVONNE EYLER, PH.D.  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600